Article in European journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Rishi RikhiCenter for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Department of Cardiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.ORCID 0000-0002-8013-4564
Haiying ChenDepartment of Biostatistics and Data Science, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
John Jeffrey CarrDepartment of Radiology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Michael D ShapiroCenter for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Department of Cardiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Alain G BertoniDivision of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID 0000-0002-7503-6273
Funding
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Task Area A Core Study Operations.Task Area A shall encompass annual follow-up of cohort members, clinical endpoints ascertainment, study coordination activities, maintenance of the database and biosp75N92020D00001 · NHLBI · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, ROBYN LEAGH · 2020 to 2025
$17.2M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
TO EXERCISE OPTION PERIOD ONE (1) FOR TASK AREA A - MESA CORE OPERATIONS, FIELD CENTER.75N92020D00004 · NHLBI · NORTHWESTERN UNIVERSITY · PI SIEGEL, JONATHAN H · 2020 to 2025
$4.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00006 · NHLBI · UNIVERSITY OF MINNESOTA · PI PANKOW, JAMES S · 2020 to 2025
$4.4M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00003 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POST, WENDY S · 2020 to 2025
$3.8M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00007 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BERTONI, ALAIN GERALD · 2020 to 2025
$3.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00002 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEA, STEVEN J · 2020 to 2025
$3.4M
SUBCLINICAL CARDIOVASCULAR DISEASE STUDYN01HC095166 · HC · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI TRACY, RUSSELL P · 1999 to 2001
$758k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY-FIELD CENTERN01HC095162 · HC · JOHNS HOPKINS UNIVERSITY · PI SZKLO, MOYSES A · 1999 to 2000
aimsThe 2023 American Heart Association Predicting Risk of Cardiovascular Disease (CVD) EVENTs (PREVENT) risk equations allow for 10- and 30-year atherosclerotic CVD (ASCVD) quantitative risk assessment. We investigated the relationship between PREVENT 10-year and 30-year ASCVD risk categories with coronary artery calcium (CAC) and incident ASCVD.
methodsThis analysis included participants from the Multi-Ethnic Study of Atherosclerosis with CAC measured by computed tomography and calculated PREVENT (N=6,747) risk score. Prevalent, incident, and CAC progression, as well as incident ASCVD, were compared by clinical 10-year risk categories and 30-year risk cut points based on a framework categorizing lifetime risk of ASCVD; low risk was defined as < the mean 30 year PREVENT estimate for participants without ASCVD risk factors (<11%).
resultsThe cohort mean age was 62.2 years and was 52.8% female, and 61.5% non-White. Individuals with low 10-year PREVENT ASCVD risk (<5%) and elevated PREVENT 30-year ASCVD risk (≥11%) had a higher prevalence of CAC compared to those low-risk for both 10-year and 30-year metrics. Incident CAC followed a similar pattern. CAC progression was similar across risk thresholds for both risk equations. Individuals with low 10 -year PREVENT risk but elevated 30-year risk had a higher incidence of ASCVD events compared to those with those low by both metrics [hazard ratio 2.21; 95% confidence interval (1.62, 2.94)].
conclusionIndividuals with low 10-year PREVENT ASCVD predicted risk (<5%) may benefit from 30-year ASCVD risk estimation when uncertainty remains regarding further risk stratification or initiation of preventive therapies.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Relationship between 10- and 30-year PREVENT Risk Scores with Coronary Artery Calcium and Incident Atherosclerotic Cardiovascular Disease: MESA. · full record | OpenQuestion